View in EDS

Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.

Saved in:
Bibliographic Details
Title: Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
Authors: Laban, Simon1,2 simon.laban@gmail.com, Steinmeister, Leonhard1,2, Gleißner, Lisa2, Grob, Tobias J.3, Grénman, Reidar4, Petersen, Cordula2, Gal, Andreas5, Knecht, Rainald1, Dikomey, Ekkehard2, Kriegs, Malte2
Source: Radiotherapy & Oncology. Nov2013, Vol. 109 Issue 2, p286-292. 7p.
Subjects: Nicotinamide, Head & neck cancer treatment, Cancer cells, Cancer radiotherapy, Health outcome assessment, Cancer chemotherapy, Combination drug therapy
Abstract: Abstract: Background and purpose: There is a great need to improve the outcome of locoregionally advanced squamous cell carcinomas of the head and neck (HNSCC). Standard treatment includes a combination of surgery, radio- and chemotherapy. The addition of molecular targeting agents to conventional treatment may improve outcomes. In this study the Raf inhibitor sorafenib was used to increase the radiosensitivity of HNSCC cell lines. Material and methods: In a panel of six cell lines (A549, FaDu, UTSCC 60A, UTSCC 42A, UTSCC 42B, UTSCC 29) radiosensitivity was measured by colony formation assay and apoptosis and cell cycle analysis were performed by flow cytometry. DNA repair was analyzed by 53BP1 immunohistochemistry. Results: Sorafenib added prior to irradiation resulted in an increased cellular radiosensitivity (DEF0.5 =1.11–1.84). Radiosensitization was not caused by an enhanced rate of apoptosis or cell cycle effects. In contrast, sorafenib was shown for the first time to block the repair of DNA double-strand breaks (DSB). Conclusion: Our data suggest that sorafenib may be used to overcome the radioresistance of HNSCC through the inhibition of DSB repair. [Copyright &y& Elsevier]
Copyright of Radiotherapy & Oncology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
FullText Text:
  Availability: 0
Header DbId: egs
DbLabel: Engineering Source
An: 92715292
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Laban%2C+Simon%22">Laban, Simon</searchLink><relatesTo>1,2</relatesTo><i> simon.laban@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Steinmeister%2C+Leonhard%22">Steinmeister, Leonhard</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Gleißner%2C+Lisa%22">Gleißner, Lisa</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Grob%2C+Tobias+J%2E%22">Grob, Tobias J.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Grénman%2C+Reidar%22">Grénman, Reidar</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Petersen%2C+Cordula%22">Petersen, Cordula</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Gal%2C+Andreas%22">Gal, Andreas</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Knecht%2C+Rainald%22">Knecht, Rainald</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Dikomey%2C+Ekkehard%22">Dikomey, Ekkehard</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Kriegs%2C+Malte%22">Kriegs, Malte</searchLink><relatesTo>2</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Radiotherapy+%26+Oncology%22">Radiotherapy & Oncology</searchLink>. Nov2013, Vol. 109 Issue 2, p286-292. 7p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Nicotinamide%22">Nicotinamide</searchLink><br /><searchLink fieldCode="DE" term="%22Head+%26+neck+cancer+treatment%22">Head & neck cancer treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+cells%22">Cancer cells</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+radiotherapy%22">Cancer radiotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Health+outcome+assessment%22">Health outcome assessment</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+chemotherapy%22">Cancer chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Combination+drug+therapy%22">Combination drug therapy</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Abstract: Background and purpose: There is a great need to improve the outcome of locoregionally advanced squamous cell carcinomas of the head and neck (HNSCC). Standard treatment includes a combination of surgery, radio- and chemotherapy. The addition of molecular targeting agents to conventional treatment may improve outcomes. In this study the Raf inhibitor sorafenib was used to increase the radiosensitivity of HNSCC cell lines. Material and methods: In a panel of six cell lines (A549, FaDu, UTSCC 60A, UTSCC 42A, UTSCC 42B, UTSCC 29) radiosensitivity was measured by colony formation assay and apoptosis and cell cycle analysis were performed by flow cytometry. DNA repair was analyzed by 53BP1 immunohistochemistry. Results: Sorafenib added prior to irradiation resulted in an increased cellular radiosensitivity (DEF0.5 =1.11–1.84). Radiosensitization was not caused by an enhanced rate of apoptosis or cell cycle effects. In contrast, sorafenib was shown for the first time to block the repair of DNA double-strand breaks (DSB). Conclusion: Our data suggest that sorafenib may be used to overcome the radioresistance of HNSCC through the inhibition of DSB repair. [Copyright &y& Elsevier]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Radiotherapy & Oncology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=92715292
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.radonc.2013.07.003
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 286
    Subjects:
      – SubjectFull: Nicotinamide
        Type: general
      – SubjectFull: Head & neck cancer treatment
        Type: general
      – SubjectFull: Cancer cells
        Type: general
      – SubjectFull: Cancer radiotherapy
        Type: general
      – SubjectFull: Health outcome assessment
        Type: general
      – SubjectFull: Cancer chemotherapy
        Type: general
      – SubjectFull: Combination drug therapy
        Type: general
    Titles:
      – TitleFull: Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Laban, Simon
      – PersonEntity:
          Name:
            NameFull: Steinmeister, Leonhard
      – PersonEntity:
          Name:
            NameFull: Gleißner, Lisa
      – PersonEntity:
          Name:
            NameFull: Grob, Tobias J.
      – PersonEntity:
          Name:
            NameFull: Grénman, Reidar
      – PersonEntity:
          Name:
            NameFull: Petersen, Cordula
      – PersonEntity:
          Name:
            NameFull: Gal, Andreas
      – PersonEntity:
          Name:
            NameFull: Knecht, Rainald
      – PersonEntity:
          Name:
            NameFull: Dikomey, Ekkehard
      – PersonEntity:
          Name:
            NameFull: Kriegs, Malte
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2013
              Type: published
              Y: 2013
          Identifiers:
            – Type: issn-print
              Value: 01678140
          Numbering:
            – Type: volume
              Value: 109
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Radiotherapy & Oncology
              Type: main
ResultId 1